Citius pharmaceuticals, inc. and citius oncology, inc. announce promising preliminary results of an investigator-initiated phase i clinical trial of pembrolizumab (keytruda®) and lymphir™ in cancer patients with recurrent solid tumors

Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled 27% objective response rate (orr) 33% clinical benefit rate (cbr) with a median progression free survival (pfs) of 57 weeks chemotherapy-free immunomodulatory regimen well-tolerated with no documented serious immune-related adverse events cranford, n.j. , nov. 11, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius pharma" or the "company") (nasdaq: ctxr) and citius oncology, inc. ("citius oncology") (nasdaq: ctor), today announced promising preliminary results from an ongoing investigator-initiated phase i clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and lymphir™ (denileukin diftitox-cxdl or e7777) in patients with recurrent solid tumors.
CTXR Ratings Summary
CTXR Quant Ranking